Caroline A. Larregieu, Ph.D.
Affiliations: | 2014 | Pharmaceutical Sciences and Pharmacogenomics | University of California, San Francisco, San Francisco, CA |
Area:
Pharmacy, PharmacologyGoogle:
"Caroline Larregieu"Parents
Sign in to add mentorLeslie Z. Benet | grad student | 2014 | UCSF | |
(Resolving the Conflict between BCS and BDDCS for the Advancement of the Drug Discovery, Development, and Regulatory Processes.) |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Li J, Larregieu CA, Benet LZ. (2016) Classification of natural products as sources of drugs according to the biopharmaceutics drug disposition classification system (BDDCS). Chinese Journal of Natural Medicines. 14: 888-897 |
Liu M, Li W, Larregieu CA, et al. (2014) Development of synthetic peptide-modified liposomes with LDL receptor targeting capacity and improved anticancer activity. Molecular Pharmaceutics. 11: 2305-12 |
Larregieu CA, Benet LZ. (2014) Distinguishing between the permeability relationships with absorption and metabolism to improve BCS and BDDCS predictions in early drug discovery. Molecular Pharmaceutics. 11: 1335-44 |
Larregieu CA, Benet LZ. (2013) Drug discovery and regulatory considerations for improving in silico and in vitro predictions that use Caco-2 as a surrogate for human intestinal permeability measurements. The Aaps Journal. 15: 483-97 |
Broccatelli F, Larregieu CA, Cruciani G, et al. (2012) Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Advanced Drug Delivery Reviews. 64: 95-109 |
Benet LZ, Larregieu CA. (2010) The FDA should eliminate the ambiguities in the current BCS biowaiver guidance and make public the drugs for which BCS biowaivers have been granted. Clinical Pharmacology and Therapeutics. 88: 405-7 |